

bsm-33107M**[Primary Antibody]**

Bioss
ANTIBODIES

www.bioss.com.cn

sales@bioss.com.cn

techsupport@bioss.com.cn

400-901-9800


Histone H3(di methyl K27) Mouse mAb

— DATASHEET —


Host: Mouse	Isotype: IgG1
Clonality: Monoclonal	CloneNo.: 5C11
GeneID: 8350	SWISS: P68431
Target: Histone H3(di methyl K27)	
Immunogen: KLH conjugated synthesised methylpeptide derived from human Histone H3 around the methylation site of di methyl K27: AR(di Methyl-K)SA.	
Purification: affinity purified by Protein G	
Concentration: 1mg/ml	
Storage: Size : 50ul/100ul/200ul 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Size : 200ug (PBS only) 0.01M PBS Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.	
Background: Modulation of the chromatin structure plays an important role in the regulation of transcription in eukaryotes. The nucleosome, made up of four core histone proteins (H2A, H2B, H3 and H4), is the primary building block of chromatin. The N-terminal tail of core histones undergoes different posttranslational modifications including acetylation, phosphorylation and methylation. These modifications occur in response to cell signal stimuli and have a direct effect on gene expression. In most species, the histone H2B is primarily acetylated at lysines 5, 12, 15 and 20. Histone H3 is primarily acetylated at lysines 9, 14, 18 and 23. Acetylation at lysine 9 appears to have a dominant role in histone deposition and chromatin assembly in some organisms. Phosphorylation at Ser10 of histone H3 is tightly correlated with chromosome condensation during both mitosis and meiosis.	

Applications: WB (1:500-2000)**IHC-P** (1:100-500)**IHC-F** (1:100-500)**IF** (1:100-500)**Reactivity:** Human, Mouse, Rat**Predicted MW.:** 15 kDa**Subcellular Location:** Nucleus


— VALIDATION IMAGES —



25 ug total protein per lane of various lysates (see on figure) probed with Histone H3(di methyl K27) monoclonal antibody, unconjugated (bsm-33107M) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.



Paraformaldehyde-fixed, paraffin embedded (rat pancreas); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Histone H3(di methyl K27)) Monoclonal Antibody, Unconjugated (bsm-33107M) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Mouse)(sp-0024) instructions and DAB staining.



Paraformaldehyde-fixed, paraffin embedded (human breast); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Histone H3(di methyl K27)) Monoclonal Antibody, Unconjugated (bsm-33107M) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Mouse)(sp-0024) instructions and DAB staining.

— SELECTED CITATIONS —

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

- **[IF=3.5]** Di Wu. et al. Discovery of novel pyridone-benzamide derivatives possessing a 1-methyl-2-benzimidazolinone moiety as potent EZH2 inhibitors for the treatment of B-cell lymphomas. BIOORGAN MED CHEM. 2024 Apr;;117725 WB ;Human. 38640588